Summary & Overview
HCPCS Level II J8560: Etoposide, Oral 50 mg
HCPCS Level II code J8560 designates oral etoposide in a 50 mg unit dose. As an oral chemotherapeutic agent, etoposide is used across oncology settings for a range of malignancies. Accurate coding of oral antineoplastics matters nationally because it affects benefit design, claims adjudication, and data capture for quality and utilization monitoring.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, an outline of common payer coverage considerations, and benchmark-focused content where available. The publication highlights billing and site-of-service implications relevant to outpatient and specialty pharmacy distribution, including how oral chemotherapy is typically categorized for benefit administration and claims processing.
This summary equips revenue leaders, clinical pharmacists, and payers with the essential facts about J8560, clarifies where to expect this code to appear on service lines, and identifies areas where additional payer-specific policy review may be needed. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J8560 represents etoposide; oral, 50 mg. This code describes a commercially prepared oral formulation of the chemotherapeutic agent etoposide, typically provided as a unit dose of 50 milligrams for administration by the patient.
Service Type: Oral chemotherapy medication
Typical Site of Service: Outpatient clinic, infusion center with oral on-site dispensing, specialty pharmacy or patient self-administration at home
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving systemic chemotherapy for a solid tumor or hematologic malignancy where oral etoposide is prescribed as part of a multi-agent regimen or as single-agent palliative therapy. The patient presents to the outpatient oncology clinic or infusion center for evaluation; the oncologist prescribes J8560 (etoposide; oral, 50 mg) to be dispensed by the clinic pharmacy or an external specialty pharmacy. The clinical workflow includes medication reconciliation, verification of oral etoposide dose (for example, total daily mg converted into 50 mg tablet counts), counseling on administration (timing relative to food, handling), review of baseline labs (complete blood count, liver and renal function), documentation of intent of therapy (curative, adjuvant, neoadjuvant, or palliative), and scheduling follow-up labs and visits. If oral etoposide is dispensed in the clinic, billing uses the HCPCS Level II code J8560 with appropriate unit calculation based on number of 50 mg tablets provided. Typical sites of service are outpatient oncology clinics, physician office-based infusion centers, and specialty pharmacy dispensing for home administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit for evaluation and management |